Trevena (NASDAQ:TRVN)‘s stock had its “buy” rating restated by equities research analysts at Oppenheimer in a research note issued to investors on Thursday.
Several other research firms have also recently weighed in on TRVN. HC Wainwright lifted their price objective on shares of Trevena to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Zacks Investment Research lowered shares of Trevena from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research note on Saturday, January 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $7.06.
Trevena stock traded down $0.03 during midday trading on Thursday, hitting $1.76. 176,075 shares of the company were exchanged, compared to its average volume of 886,950. Trevena has a fifty-two week low of $1.34 and a fifty-two week high of $3.98. The company has a quick ratio of 3.71, a current ratio of 3.71 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $112.73, a price-to-earnings ratio of -1.46 and a beta of -0.61.
Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.02. analysts forecast that Trevena will post -0.89 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in TRVN. Millennium Management LLC bought a new position in shares of Trevena during the 4th quarter worth about $130,000. American Century Companies Inc. acquired a new position in Trevena in the fourth quarter valued at approximately $135,000. California State Teachers Retirement System lifted its holdings in Trevena by 0.5% in the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 500 shares during the period. Bourgeon Capital Management LLC lifted its holdings in Trevena by 59.3% in the fourth quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 51,300 shares during the period. Finally, Virtu Financial LLC lifted its holdings in Trevena by 1,546.1% in the fourth quarter. Virtu Financial LLC now owns 191,701 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 180,055 shares during the period. 50.47% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Trevena (TRVN) Rating Reiterated by Oppenheimer” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://ledgergazette.com/2018/03/22/trevena-trvn-rating-reiterated-by-oppenheimer.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.